58 trials changed in the last 30 days: 0 stopped, 16 with notable changes, 42 with minor changes only.
Primary completion pushed from Aug 31, 2026 to May 25, 2028
Also in this update: Trial sites reduced: 178 → 171 locations; Study completion pushed from Mar 31, 2029 to Aug 31, 2029
Hoffmann-La RochePhase 3 NCT05797610 Registry history of NCT05797610 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 27, 2026 to Feb 5, 2028
Also in this update: Enrollment increased: 240 → 330 participants; Trial sites reduced: 50 → 46 locations
Hoffmann-La RochePhase 2 NCT07112872 Registry history of NCT07112872 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027
Hoffmann-La RochePhase 1/2 NCT02650401 Registry history of NCT02650401 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Oct 14, 2026; Trial completed
Hoffmann-La RochePhase 3 NCT05627557 Registry history of NCT05627557 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Hoffmann-La RochePhase 1 NCT07749157 Registry history of NCT07749157 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Hoffmann-La RochePhase 3 NCT05199688 Registry history of NCT05199688 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Sep 28, 2026; Trial sites reduced: 148 → 141 locations
Hoffmann-La RochePhase 3 NCT04660344 Registry history of NCT04660344 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 3 → Phase 2
Also in this update: Primary completion pushed from Aug 1, 2029 to Aug 31, 2029; Study completion pushed from Aug 1, 2031 to Jul 30, 2032
Hoffmann-La RochePhase 2 NCT07503340 Registry history of NCT07503340 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 1/2 → Phase 1
Also in this update: Trial completed
Genentech, Inc.Phase 1 NCT06693908 Registry history of NCT06693908 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Hoffmann-La RochePhase 3 NCT07843485 Registry history of NCT07843485 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations
Hoffmann-La RochePhase 3 NCT07843498 Registry history of NCT07843498 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations
Hoffmann-La RochePhase 3 NCT07843472 Registry history of NCT07843472 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Hoffmann-La RocheNot specified NCT07827586 Registry history of NCT07827586 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 16, 2026
Genentech, Inc.Phase 2 NCT05037929 Registry history of NCT05037929 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 9, 2026
Hoffmann-La RochePhase 3 NCT03456063 Registry history of NCT03456063 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 9, 2026
Hoffmann-La RochePhase 3 NCT03194893 Registry history of NCT03194893 on ClinicalTrials.gov (opens the registry)
Trial completed
Hoffmann-La RochePhase 2 NCT05548556 Registry history of NCT05548556 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 31, 2040 to Aug 27, 2026; Final enrollment: 400 participants (planned 500)
Genentech, Inc.Not specified NCT01733082 Registry history of NCT01733082 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 200 → 168 locations; Primary completion moved earlier from Jan 30, 2027 to Oct 29, 2026
Hoffmann-La RochePhase 3 NCT06588855 Registry history of NCT06588855 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Trial sites expanded: 155 → 216 locations; Study completion date changed from estimate of Aug 31, 2027 to Aug 26, 2026
Hoffmann-La RochePhase 3 NCT02486718 Registry history of NCT02486718 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Jun 7, 2028 to Feb 16, 2028; Final enrollment: 1101 participants (planned 800)
Hoffmann-La RochePhase 3 NCT07169578 Registry history of NCT07169578 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 150 → 147 locations; Primary and study completion moved earlier from Jun 7, 2028 to Feb 16, 2028
Hoffmann-La RochePhase 3 NCT07170150 Registry history of NCT07170150 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jun 30, 2026 to Nov 17, 2025
Hoffmann-La RochePhase 3 NCT04665856 Registry history of NCT04665856 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 18 → 9 locations
Hoffmann-La RochePhase 1 NCT06624085 Registry history of NCT06624085 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Hoffmann-La RocheNot specified NCT05954910 Registry history of NCT05954910 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2027 to Jun 15, 2028
And 2 more changes in the last 30 days
Hoffmann-La RochePhase 3 NCT05296798 Registry history of NCT05296798 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 31, 2028 to Oct 31, 2028
Hoffmann-La RocheNot specified NCT07527741 Registry history of NCT07527741 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 24, 2024 to Oct 24, 2024
Hoffmann-La RochePhase 2 NCT04980222 Registry history of NCT04980222 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Mar 1, 2027 to May 11, 2027
Hoffmann-La RochePhase 1 NCT07271693 Registry history of NCT07271693 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 4, 2026 to Nov 16, 2026
Also in this update: Study completion pushed from Sep 6, 2026 to Nov 16, 2026
Genentech, Inc.Phase 1 NCT07144111 Registry history of NCT07144111 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 203 → 209 locations
Hoffmann-La RochePhase 3 NCT07351045 Registry history of NCT07351045 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 75 → 93 locations
Hoffmann-La RochePhase 3 NCT07555938 Registry history of NCT07555938 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 46 locations
Also in this update: Start date changed from estimate of Sep 30, 2026 to Oct 6, 2026
Hoffmann-La RochePhase 3 NCT07541170 Registry history of NCT07541170 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 204 → 210 locations
Hoffmann-La RochePhase 3 NCT07351058 Registry history of NCT07351058 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 34 locations
Hoffmann-La RochePhase 3 NCT07717411 Registry history of NCT07717411 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 6 locations
Hoffmann-La RochePhase 1/2 NCT07226206 Registry history of NCT07226206 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 77 → 56 locations
Hoffmann-La RochePhase 3 NCT05503264 Registry history of NCT05503264 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 22 → 26 locations
Hoffmann-La RochePhase 3 NCT07158242 Registry history of NCT07158242 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 280 → 288 locations
Hoffmann-La RochePhase 3 NCT06793215 Registry history of NCT06793215 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 186 → 206 locations
Hoffmann-La RochePhase 2/3 NCT07413939 Registry history of NCT07413939 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 59 → 54 locations
Genentech, Inc.Phase 2 NCT06096779 Registry history of NCT06096779 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 42 → 59 locations
Hoffmann-La RochePhase 3 NCT07416604 Registry history of NCT07416604 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 14 → 17 locations
Hoffmann-La RochePhase 3 NCT07298421 Registry history of NCT07298421 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 108 → 114 locations
Hoffmann-La RochePhase 2 NCT07282574 Registry history of NCT07282574 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 64 → 74 locations
Genentech, Inc.Phase 1/2 NCT07100106 Registry history of NCT07100106 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 73 → 77 locations
Hoffmann-La RochePhase 3 NCT05862285 Registry history of NCT05862285 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 199 → 203 locations
Hoffmann-La RochePhase 3 NCT06819891 Registry history of NCT06819891 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 27 → 32 locations
Hoffmann-La RochePhase 3 NCT07416526 Registry history of NCT07416526 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 212 → 229 locations
Hoffmann-La RochePhase 3 NCT07177352 Registry history of NCT07177352 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 21 → 25 locations
Hoffmann-La RochePhase 1 NCT06884618 Registry history of NCT06884618 on ClinicalTrials.gov (opens the registry)
Start date pushed from Oct 1, 2026 to Oct 30, 2026
Hoffmann-La RochePhase 2 NCT07825064 Registry history of NCT07825064 on ClinicalTrials.gov (opens the registry)
Primary and study completion moved earlier from Dec 31, 2026 to Nov 30, 2026
Hoffmann-La RochePhase 3 NCT03148418 Registry history of NCT03148418 on ClinicalTrials.gov (opens the registry)
Final enrollment: 56 participants (planned 50)
Hoffmann-La RochePhase 1 NCT06903065 Registry history of NCT06903065 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Aug 31, 2028 to Feb 21, 2028
Hoffmann-La RochePhase 3 NCT04544436 Registry history of NCT04544436 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Feb 28, 2027 to Jul 21, 2027
Hoffmann-La RochePhase 3 NCT04544449 Registry history of NCT04544449 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 8, 2026 to Oct 6, 2026
Hoffmann-La RochePhase 1 NCT07416552 Registry history of NCT07416552 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 26, 2026 to Jun 30, 2027
Hoffmann-La RochePhase 2 NCT05119569 Registry history of NCT05119569 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Chugai PharmaceuticalPhase 1 NCT05022927 Registry history of NCT05022927 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-09 | NCT07867262 A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant… | Phase 1 | Not Yet Recruiting |
| 2026-10-05 | NCT07859085 A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in… | Phase 1 | Not Yet Recruiting |
| 2026-10-01 | NCT07851259 A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic… | Phase 2 | Not Yet Recruiting |
| 2026-09-29 | NCT07846683 A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in… | Phase 3 | Not Yet Recruiting |
| 2026-09-28 | NCT07843472 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… | Phase 3 | Recruiting |
| 2026-09-28 | NCT07843485 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… | Phase 3 | Recruiting |
| 2026-09-28 | NCT07843498 A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… | Phase 3 | Recruiting |
| 2026-09-24 | NCT07838194 Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and… | Phase 3 | Not Yet Recruiting |
| 2026-09-22 | NCT07835243 A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of… | Phase 1 | Not Yet Recruiting |
| 2026-09-18 | NCT07827573 A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 55 | |
| Phase 1/2 | 25 | |
| Phase 2 | 52 | |
| Phase 2/3 | 4 | |
| Phase 3 | 88 | |
| Phase 4 | 10 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT05861999 | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric… | Muscular Atrophy, Spinal | Recruiting | 2026-10-13 |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies | Breast Cancer | Recruiting | 2026-10-06 |
| NCT04853251 | A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… | Neovascular Age-related Macular Degeneration | Recruiting | 2026-10-02 |
| NCT05861986 | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early… | Muscular Atrophy, Spinal | Recruiting | 2026-10-02 |
| NCT07609719 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… | Multiple Sclerosis | Recruiting | 2026-09-30 |
| NCT07483450 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… | Relapsing Multiple Sclerosis | Active, Not Recruiting | 2026-09-30 |
| NCT05232929 | Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy | Active, Not Recruiting | 2026-09-09 |
| NCT05224102 | A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented… | Diabetic Macular Edema | Active, Not Recruiting | 2026-08-25 |
| NCT06795048 | A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants… | Neovascular Age-related Macular Degeneration (nAMD) | Active, Not Recruiting | 2026-07-31 |
| NCT05181618 | A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants… | Severe Hemophilia A | Active, Not Recruiting | 2026-07-27 |
| Phase 3 | ||||
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo… | Metastatic Breast Cancer | Recruiting | 2026-10-16 |
| NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With… | Moderately to Severely Active Crohns Disease | Recruiting | 2026-10-16 |
| NCT06847542 | A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD | Neovascular Age-related Macular Degeneration | Recruiting | 2026-10-15 |
| NCT07177352 | Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's… | Alzheimers Disease | Recruiting | 2026-10-15 |
| NCT07351045 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… | Obesity or Overweight | Recruiting | 2026-10-13 |
| NCT07351058 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… | Obesity or Overweight | Recruiting | 2026-10-13 |
| NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's… | Non-small Cell Lung Cancer | Recruiting | 2026-10-13 |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… | Multiple Myeloma | Recruiting | 2026-10-13 |
| NCT07717411 | A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to… | Alzheimer's Disease | Recruiting | 2026-10-13 |
| NCT06998524 | A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von… | Von Willebrand Disease, Type 3 | Recruiting | 2026-10-09 |
| NCT07541079 | A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant… | Early Breast Cancer | Recruiting | 2026-10-09 |
| NCT07670416 | A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or… | Obesity | Recruiting | 2026-10-08 |
| NCT07843472 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… | Obesity or Overweight | Recruiting | 2026-10-07 |
| NCT07843485 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… | Obesity or Overweight | Recruiting | 2026-10-07 |
| NCT07843498 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants… | Obesity or Overweight | Recruiting | 2026-10-07 |
Breast Cancer (31) · Multiple Sclerosis (24) · Lung Cancer (20) · Non-Small Cell Lung Cancer (NSCLC) (17) · Non-Hodgkin Lymphoma (16) · Dementia (11) · Obesity (11) · Multiple Myeloma (10) · Alzheimer's Disease (8) · Diabetes (8)